Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort.
Pinheiro MM, Pileggi GS, Kakehasi AM, Gomides Reis APM, Reis-Neto ET, Abreu MM, Albuquerque CP, Araújo NC, Bacchiega AB, Bianchi DV, Bica B, Bonfa E, Borba EF, Egypto Brito DCS, Calderaro DC, Pinto Duarte ÂLB, Espírito Santo RC, Fernandes PR, Guimarães MP, Poti Gomes KW, Faustino Ilana GG, Klumb EM, Marques CDL, Guedes de Melo AK, Monticielo OA, Mota LMH, Munhoz GA, Paiva ES, Pereira HLA, Provenza JR, Ribeiro SLE, Rocha LF Jr, Sato EI, Skare T, de Souza VA, Valim V, Lacerda MVG, Xavier RM, Ferreira GA.
Pinheiro MM, et al. Among authors: kakehasi am.
Clin Exp Rheumatol. 2022 Jul;40(7):1258-1266. doi: 10.55563/clinexprheumatol/67oyux. Epub 2021 Jul 7.
Clin Exp Rheumatol. 2022.
PMID: 34251312
Free article.